Literature DB >> 23627345

A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation.

Laura C Barr1, Mairi Brittan, Andrew Conway Morris, Daniel F McAuley, Chiara McCormack, Alison M Fletcher, Hamish Richardson, Martin Connell, Dilip Patel, William A H Wallace, Adriano G Rossi, Donald J Davidson, Lynn Manson, Marc Turner, Nikhil Hirani, Timothy S Walsh, Niall H Anderson, Kevin Dhaliwal, A John Simpson.   

Abstract

RATIONALE: Depletion of monocytes reduces LPS-induced lung inflammation in mice, suggesting monocytes as potential therapeutic targets in acute lung injury.
OBJECTIVES: To investigate whether depletion of circulating blood monocytes has beneficial effects on markers of systemic and pulmonary inflammation in a human model of acute lung inflammation.
METHODS: A total of 30 healthy volunteers were enrolled in a randomized controlled trial. Volunteers inhaled LPS at baseline, and were randomized to receive active mononuclear cell depletion by leukapheresis, or sham leukapheresis, in a double-blind fashion (15 volunteers per group). Serial blood counts were measured, bronchoalveolar lavage (BAL) was performed at 9 hours, and [(18)F]fluorodeoxyglucose positron emission tomography at 24 hours. The primary endpoint was the increment in circulating neutrophils at 8 hours.
MEASUREMENTS AND MAIN RESULTS: As expected, inhalation of LPS induced neutrophilia and an up-regulation of inflammatory mediators in the blood and lungs of all volunteers. There was no significant difference between the depletion and sham groups in the mean increment in blood neutrophil count at 8 hours (6.16 × 10(9)/L and 6.15 × 10(9)/L, respectively; P = 1.00). Furthermore, there were no significant differences in BAL neutrophils or protein, positron emission tomography-derived measures of global lung inflammation, or cytokine levels in plasma or BAL supernatant between the study groups. No serious adverse events occurred, and no symptoms were significantly different between the groups.
CONCLUSIONS: These findings do not support a role for circulating human monocytes in the early recruitment of neutrophils during LPS-mediated acute lung inflammation in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627345     DOI: 10.1164/rccm.201212-2334OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

Review 1.  Diverse macrophage populations mediate acute lung inflammation and resolution.

Authors:  Neil R Aggarwal; Landon S King; Franco R D'Alessio
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-07       Impact factor: 5.464

2.  Bolus intravenous 0.9% saline leads to interstitial permeability pulmonary edema in healthy volunteers.

Authors:  Hanmo Li; Andrew Bersten; Ubbo Wiersema; David Schembri; Elena Cavallaro; Dani-Louise Dixon; Shailesh Bihari
Journal:  Eur J Appl Physiol       Date:  2021-09-04       Impact factor: 3.078

Review 3.  The role of lung macrophages in acute respiratory distress syndrome.

Authors:  Wenpei Dang; Yiming Tao; Xinxin Xu; Hui Zhao; Lijuan Zou; Yongsheng Li
Journal:  Inflamm Res       Date:  2022-10-20       Impact factor: 6.986

4.  Inhibition of Caspase-1 with Tetracycline Ameliorates Acute Lung Injury.

Authors:  Konrad Peukert; Mario Fox; Susanne Schulz; Caroline Feuerborn; Stilla Frede; Christian Putensen; Hermann Wrigge; Beate Mareike Kümmerer; Sascha David; Benjamin Seeliger; Tobias Welte; Eicke Latz; Dennis Klinman; Christoph Wilhelm; Folkert Steinhagen; Christian Bode
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

5.  Functional characterisation of human pulmonary monocyte-like cells in lipopolysaccharide-mediated acute lung inflammation.

Authors:  Mairi Brittan; Laura C Barr; Niall Anderson; Andrew Conway Morris; Rodger Duffin; John A Marwick; Fiona Rossi; Shonna Johnson; Kev Dhaliwal; Nikhil Hirani; Adriano G Rossi; A John Simpson
Journal:  J Inflamm (Lond)       Date:  2014-03-31       Impact factor: 4.981

6.  Exposure of Monocytic Cells to Lipopolysaccharide Induces Coordinated Endotoxin Tolerance, Mitochondrial Biogenesis, Mitophagy, and Antioxidant Defenses.

Authors:  John D Widdrington; Aurora Gomez-Duran; Angela Pyle; Marie-Helene Ruchaud-Sparagano; Jonathan Scott; Simon V Baudouin; Anthony J Rostron; Penny E Lovat; Patrick F Chinnery; A John Simpson
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

7.  Lipopolysaccharide inhalation recruits monocytes and dendritic cell subsets to the alveolar airspace.

Authors:  Laura Jardine; Sarah Wiscombe; Gary Reynolds; David McDonald; Andrew Fuller; Kile Green; Andrew Filby; Ian Forrest; Marie-Helene Ruchaud-Sparagano; Jonathan Scott; Matthew Collin; Muzlifah Haniffa; A John Simpson
Journal:  Nat Commun       Date:  2019-04-30       Impact factor: 14.919

8.  A novel role for myeloid endothelin-B receptors in hypertension.

Authors:  Alicja Czopek; Rebecca Moorhouse; Léa Guyonnet; Tariq Farrah; Olivia Lenoir; Elizabeth Owen; Job van Bragt; Hannah M Costello; Filippo Menolascina; Véronique Baudrie; David J Webb; David C Kluth; Matthew A Bailey; Pierre-Louis Tharaux; Neeraj Dhaun
Journal:  Eur Heart J       Date:  2019-03-01       Impact factor: 29.983

9.  Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury.

Authors:  Alastair Proudfoot; Andrew Bayliffe; Cecilia M O'Kane; Mark Griffiths; Charlotte Summers; Daniel Francis McAuley; Tracey Wright; Adrian Serone; Philippe Jean Bareille; Vanessa Brown; Umar I Hamid; Younan Chen; Robert Wilson; Joanna Cordy; Peter Morley; Ruud de Wildt; Stuart Elborn; Matthew Hind; Edwin R Chilvers
Journal:  Thorax       Date:  2018-01-29       Impact factor: 9.102

10.  MicroRNA-541-5p REgulates Type II Alveolar Epithelial Cell Proliferation and Activity by Modulating the HMGB1 Expression.

Authors:  Jie Shen; Jun Yan; Qiuyun Wang; Lei Zhuang; Yan Luo
Journal:  Shock       Date:  2022-04-01       Impact factor: 3.454

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.